|
Market Closed -
Nasdaq
23:00:00 26/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 148.09 USD | -0.46% |
|
+3.24% | +20.65% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 183,637 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 20.59% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 200,383 | 192,762 | 186,472 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 18.16% | -3.8% | -3.26% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.3x | 18.5x | 17x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 10.1x | 7.65x | 6.1x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 1.99x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 5.98x | 5.62x | 5.34x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.53x | 5.9x | 5.43x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 25.5x | 10.8x | 10.2x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 62.4x | 12.2x | 11x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -380x | 14.7x | 13.4x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.26% | 6.78% | 7.44% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.296 | 3.396 | 3.102 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.23% | 2.29% | 2.09% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.273 | 8.021 | 8.705 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -101% | 42.3% | 35.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,693 | 32,695 | 34,363 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,859 | 17,834 | 18,324 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,209 | 15,844 | 16,902 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,275 | 10,275 | 10,917 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 16,745 | 9,125 | 2,835 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 148.10 | 148.10 | 148.10 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 2/1/22 A | 2/2/23 A | 2/6/24 A | 2/11/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -45.46x | 6.56x | 25.6x | 2.22% | 184B | |
| 35.12x | 12.73x | 25.81x | 0.56% | 1,100B | |
| 30.38x | - | - | 1.97% | 658B | |
| 33.92x | 7.84x | 16.3x | 2.58% | 470B | |
| 20.83x | 4.94x | 12.23x | 2.67% | 372B | |
| 22.71x | 5.84x | 14.47x | 2.73% | 304B | |
| 21.88x | 4.48x | 12.79x | 1.96% | 264B | |
| 27.97x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.99x | 4.96x | 10.35x | 3.67% | 213B | |
| 17.9x | 3.38x | 8.62x | 6.03% | 163B | |
| Average | 17.93x | 6.44x | 15.44x | 2.67% | 396.57B | |
| Weighted average by Cap. | 25.00x | 8.17x | 18.06x | 2.06% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
